Roche's Oral SERD Giredestrant Shows Impressive Phase 3 Results in ESMO, Overcoming Endocrine Resistance in Breast Cancer

Oct 19, 2025 17:58 CST Updated 17:59

Roche

Oncology Drug Research, Development, and Manufacturing

Abstract:At the ESMO Congress, Roche presented the Phase 3 clinical data of the oral selective estrogen receptor degrader (SERD) giredestrant. The drug, in combination with everolimus, significantly reduced the risk of disease progression or death in patients with ER-positive, HER2-negative advanced breast cancer who had failed CDK4/6 inhibitor and endocrine therapy, showing particularly prominent efficacy in the ESR1 mutation population, offering new hope for addressing clinical drug resistance.

Core Data: Significant Benefits for Dual Populations

Roche's recently disclosed evERA breast cancer study results show that the combination therapy of giredestrant and everolimus performs impressively. In the intent-to-treat population, this combination reduced the risk of disease progression or death by 44%; in the subgroup of patients with ESR1 mutations, the risk reduction was as high as 62%, both reaching statistically significant differences.

Although the overall survival data is not yet mature, a clear positive trend has been shown in both populations. More importantly, the combination therapy was generally well-tolerated with no new safety signals, providing assurance for long-term patient use. If approved subsequently, this regimen will become the first oral SERD combination therapy after CDK inhibitor treatment failure.

Clinical Value: Breaking the Dilemma of Drug Resistance

ER-positive, HER2-negative breast cancer accounts for approximately 70% of all breast cancer cases. Endocrine therapy is the core treatment, but drug resistance has been a persistent clinical challenge. Particularly after the failure of CDK4/6 inhibitor therapy, patients have limited treatment options.

As a new generation of oral SERD, giredestrant overcomes the administration limitations of the traditional injectable fulvestrant and demonstrates significant efficacy in patients with ESR1 mutations that cause resistance. This characteristic gives it a unique advantage in addressing both primary and acquired endocrine resistance, and it is expected to reshape the treatment landscape for later-line advanced breast cancer.

Market Competition: Giants Crowd to Share the Pie

The SERD field is becoming a focal point of competition among pharmaceutical companies. Currently, several oral SERDs worldwide have entered the late-stage development phase, with Eli Lilly's imlunestrant and AstraZeneca’s camizestrant already submitted for marketing approval. Meanwhile, the first oral SERD, elacestrant, has been approved for patients with ESR1 mutations, further intensifying market competition.

Notably, the global SERD market size is projected to reach USD 2.1087 billion by 2034. However, the widespread adoption of fulvestrant generics has put considerable pressure on innovative drugs. Roche needs to continuously strengthen its efforts in differentiated efficacy and market positioning to stand out in this crowded field.

The announcement of this Phase 3 data not only lays the foundation for Roche's competition in the SERD field but also brings new treatment options to countless patients with drug-resistant breast cancer, advancing endocrine therapy for breast cancer into a new era of oral precision.

Reference Source:https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming
All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will delete the content immediately. All articles represent the views of the author and not this site.